Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 11/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15585100 | 1.00 | TBK1 (0.48) | TBK1AURKAFLT3CCNT1CCNE1 | |
| SCHEMBL15584143 | 0.85 | TBK1 (0.44) | TBK1AURKAFLT3CCNT1CCNE1 | |
| SCHEMBL16444467 | 0.85 | TBK1 (0.44) | TBK1AURKAFLT3CCNT1CCNE1 | |
| SCHEMBL16444175 | 0.85 | TBK1 (0.51) | TBK1PDPK1SIRT5TP53MAPT | |
| SCHEMBL15584658 | 0.85 | TBK1 (0.51) | TBK1PDPK1SIRT5TP53MAPT | |
| SCHEMBL15585297 | 0.83 | FLT3 (0.53) | TBK1AURKAFLT3CCNT1CCNE1 | |
| SCHEMBL15585815 | 0.82 | TBK1 (0.43) | TBK1AURKAFLT3CCNT1CCNE1 | |
| SCHEMBL16443990 | 0.81 | FLT3 (0.50) | TBK1AURKAFLT3BTKPDPK1 | |
| SCHEMBL15584682 | 0.81 | FLT3 (0.50) | TBK1AURKAFLT3BTKPDPK1 | |
| SCHEMBL16444565 | 0.80 | NTRK1 (0.44) | AURKAFLT3EGFRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2840080-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-9145415-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| EP-2840080-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | Fujifilm Corporation (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FLT3, NPM1, ABL1 | TBK1 711/4885AURKA 361/4885FLT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.